BACKGROUND: Docetaxel-cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, which it can effectively replace in this setting. We hypothesize that incorporating docetaxel into a simplified FOLFOX regimen should be a tolerable and effective option in first-line treatment of AGC. METHODS: Data were collected at six French centers from patients with metastatic or local AGC who received docetaxel, fluorouracil, leucovorin, or oxaliplatin (TEF) as first-line treatment. TEF was administered as follows: docetaxel (50 mg/m(2)), oxaliplatin (85 mg/m(2)), and leucovorin (40 mg/m(2)) on day 1, and 5-FU continuous infusion for 48 h (2400 mg/m(2)) every 2 weeks. RESULTS: Forty-one patients were enrolled. Performance status was grade 0 and 1 in respectively 27 and 58 % of patients; 17 patients had adenocarcinoma of the gastroesophageal junction; 37 patients had metastatic disease, 22 had a poorly differentiated or diffuse type. Objective response rate was 66 %, with a complete response in two patients (5 %). Median progression-free survival and overall survival were respectively 6.3 and 12.1 months. Tolerability was acceptable with no treatment-related deaths. The most frequent grade 3-4 toxicities were neutropenia (30 %) and neuropathy (12.5 %). Curative intent surgery after response to TEF was performed in seven patients (17 %). CONCLUSION: TEF is an effective first-line treatment with an acceptable toxicity profile for patients with AGC. It may allow curative resection in initially unresectable patients. TEF should now be evaluated in prospective randomized trials.
BACKGROUND:Docetaxel-cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, which it can effectively replace in this setting. We hypothesize that incorporating docetaxel into a simplified FOLFOX regimen should be a tolerable and effective option in first-line treatment of AGC. METHODS: Data were collected at six French centers from patients with metastatic or local AGC who received docetaxel, fluorouracil, leucovorin, or oxaliplatin (TEF) as first-line treatment. TEF was administered as follows: docetaxel (50 mg/m(2)), oxaliplatin (85 mg/m(2)), and leucovorin (40 mg/m(2)) on day 1, and 5-FU continuous infusion for 48 h (2400 mg/m(2)) every 2 weeks. RESULTS: Forty-one patients were enrolled. Performance status was grade 0 and 1 in respectively 27 and 58 % of patients; 17 patients had adenocarcinoma of the gastroesophageal junction; 37 patients had metastatic disease, 22 had a poorly differentiated or diffuse type. Objective response rate was 66 %, with a complete response in two patients (5 %). Median progression-free survival and overall survival were respectively 6.3 and 12.1 months. Tolerability was acceptable with no treatment-related deaths. The most frequent grade 3-4 toxicities were neutropenia (30 %) and neuropathy (12.5 %). Curative intent surgery after response to TEF was performed in seven patients (17 %). CONCLUSION:TEF is an effective first-line treatment with an acceptable toxicity profile for patients with AGC. It may allow curative resection in initially unresectable patients. TEF should now be evaluated in prospective randomized trials.
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: S-E Al-Batran; J T Hartmann; R Hofheinz; N Homann; V Rethwisch; S Probst; J Stoehlmacher; M R Clemens; R Mahlberg; M Fritz; G Seipelt; M Sievert; C Pauligk; A Atmaca; E Jäger Journal: Ann Oncol Date: 2008-07-31 Impact factor: 32.976
Authors: Salah-Eddin Al-Batran; Claudia Pauligk; Nils Homann; Jörg T Hartmann; Markus Moehler; Stephan Probst; Volker Rethwisch; Jan Stoehlmacher-Williams; Nicole Prasnikar; Stephan Hollerbach; Carsten Bokemeyer; Rolf Mahlberg; Ralf D Hofheinz; Kim Luley; Frank Kullmann; Elke Jäger Journal: Eur J Cancer Date: 2012-10-11 Impact factor: 9.162
Authors: P Rougier; M Ducreux; M Mahjoubi; J P Pignon; S Bellefqih; J Oliveira; C Bognel; P Lasser; M Ychou; D Elias Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: S Lorenzen; M Hentrich; C Haberl; V Heinemann; T Schuster; T Seroneit; N Roethling; C Peschel; F Lordick Journal: Ann Oncol Date: 2007-07-28 Impact factor: 32.976
Authors: Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Cindy Marabotti; Eric Van Cutsem Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: Michael J Overman; Syed M Kazmi; Jagriti Jhamb; E Lin; James C Yao; James L Abbruzzese; Linus Ho; Jaffer Ajani; Alexandria Phan Journal: Cancer Date: 2010-03-15 Impact factor: 6.860
Authors: William H Smith; Sofya Pintova; Christopher J DiMaio; Panagiotis Manolas; Dong-Seok Lee; Spiros P Hiotis; Maria Kartsonis; Randall F Holcombe; Kavita V Dharmarajan Journal: Case Rep Oncol Med Date: 2015-12-03